Retatrutide: Triple Receptor Agonist Research Overview

Retatrutide, identified in the literature by the development code LY3437943, is a synthetic peptide engineered to act as an agonist at three receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. Published work commonly refers to it as a triple hormone receptor agonist, distinguishing it from single-receptor agonists such as semaglutide and dual GIP/GLP-1 agonists such as tirzepatide.

From a structural standpoint it belongs to the same broad design lineage as other long-acting incretin analogs: a peptide backbone modified to resist rapid enzymatic degradation and to extend circulating half-life. Detailed molecular formula and molecular weight values for retatrutide are not consistently published in the peer-reviewed literature, so North Summit Labs does not state them; the lot-specific certificate issued by the testing laboratory is the authoritative record for the material you receive.

The three receptor targets are studied for distinct signaling roles. GLP-1 receptor activation is associated in the literature with glucose-dependent insulin secretion and effects on gastric emptying and satiety signaling. GIP receptor activation is likewise incretin-associated and has been investigated for complementary metabolic effects. Glucagon receptor activation has been studied in relation to hepatic glucose output and energy expenditure.

The research rationale described by investigators is that engaging all three pathways in a single molecule may produce a combined metabolic signal that differs from single- or dual-agonist engagement. This is a mechanistic framing drawn from published trial and pharmacology work, not a statement about outcomes in any individual.

Retatrutide has been studied in registered, peer-reviewed randomized trials. A phase 2 trial published in the New England Journal of Medicine in 2023 evaluated retatrutide in adults with obesity and reported dose-dependent reductions in body weight relative to placebo. A companion phase 2 trial published in The Lancet the same year evaluated retatrutide in people with type 2 diabetes and reported improvements in glycemic measures against placebo and active comparison.

More recent phase 3 work, reported as TRANSCEND-T2D-1, examined retatrutide in people with type 2 diabetes and inadequate glycemic control with diet and exercise. A separate 2026 analysis in the Journal of Clinical Endocrinology & Metabolism reported on lipid and metabolite profiles among trial participants.

Across these publications, gastrointestinal adverse events were the most frequently reported tolerability issue. These are findings from supervised clinical trials in defined patient populations; they are summarized here as literature context and do not describe or endorse any use of research-grade material.

Retatrutide is investigational. As of the most recent verifiable information, it has not been approved by the FDA or any comparable regulator for any indication, and it is not available as a prescription medicine. Any material sold outside a clinical trial context — including material sold by North Summit Labs — is a laboratory research chemical, not a medicine.

Retatrutide is supplied as a lyophilized powder in a sealed vial. General laboratory practice for lyophilized peptides applies: keep vials sealed and protected from moisture and light, allow refrigerated or frozen material to equilibrate to room temperature before opening to limit condensation, reconstitute with an appropriate solvent for the intended assay, and avoid repeated freeze-thaw cycles by aliquoting.

Handling choices are the responsibility of the investigator and should follow institutional protocols. See our laboratory storage guide for a fuller treatment of these principles.

Each retatrutide lot listed in our catalog is submitted to an independent analytical laboratory, and the resulting certificate reports identity and chromatographic purity for that specific lot. Published certificates are in the COA library, and the certificate matching the lot number on your vial is available on request.

This monograph summarizes published scientific literature for educational and reference purposes only. It is not medical, veterinary, clinical, or dosing guidance, and nothing here should be read as a claim that this compound is safe, effective, or approved for use in humans or animals.

Material supplied by North Summit Labs is intended strictly for in-vitro laboratory research by qualified professionals. It is not a drug, supplement, food, cosmetic, or medical device, and it is not for human or animal consumption. Investigators are responsible for complying with their own institutional oversight, biosafety, and legal requirements.